Research Paper|Volume 13, Issue 4|pp 5638—5649

Long non-coding RNA TP73-AS1 is a potential immune related prognostic biomarker for glioma

Bo Zhang^1,⁵, Qinglin Li^1,⁶, Bin Wu^1,^2,³, Shuyuan Zhang^1,^2,³, Liwen Li^1,^2,³, Kai Jin^1,^2,³, Sheng Li^1,⁷, Kai Li^1,⁷, Zeng Wang^1,⁶, Yi Lu^1,⁵, Liang Xia^1,^2,^3,⁴, Caixing Sun^1,^2,^3,⁴

¹Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou 310022, People’s Republic of China
²Department of Neurosurgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, People’s Republic of China
³Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China
⁴Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou 310022, People’s Republic of China
⁵Department of Integrative Chinese and Western Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China
⁶Scientific Research Department, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China
⁷Department of Medical Imaging, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China

* Equal contribution

Received: June 15, 2020Accepted: November 25, 2020Published: February 11, 2021

https://doi.org/10.18632/aging.202490

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Glioma is one of the most common primary brain tumors, and is divided into low-grade and high-grade gliomas. Long non-coding RNAs have been increasingly implicated in the pathogenesis and prognosis of glioma. Here, we demonstrated that the long non-coding RNA TP73-AS1 is differentially expressed among gliomas with different clinicopathological features in The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and GEO glioma datasets; high expression of TP73-AS1 was associated with poor clinical features, including age, stage, IDH mutation status, 1p/19q co-deletion status and overall survival. Measuring TP73-AS1 expression using real-time PCR showed the same result for 76 glioma tissue samples from our hospital. The infiltration levels of various immune cells in the tumor microenvironment were found to be significantly higher in patients with high expression of TP73-AS1. Taken together, our results suggest that TP73-AS1 has potential as a prognostic glioma biomarker. Moreover, the knowledge that TP73-AS1 affects the glioma immune microenvironment may provide new information for the immunological research and treatment of glioma.